Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven Strategy Share LOS ANGELES & BOSTON--(BUSINESS WIRE)--Vida Ventures ("Vida†), a next-generation life sciences venture firm, today announced its fourth major Vida portfolio acquisition of 2025, capping an unprecedented year of strategic exits and reinforcing the firm's disciplined, science-first approach to company building and investing. Earlier today, Halda Therapeutics ann ...

Core Insights - Orchestra BioMed Holdings, Inc. is set to host a business update call on November 12, 2025, focusing on significant clinical, strategic, and financing developments [1][2] Company Developments - The update will cover a strategic investment and collaboration expansion with Medtronic, a new capital relationship with Ligand, and a right of first refusal agreement with Terumo [2] - Enrollment in the BACKBEAT pivotal study of AVIM Therapy is accelerating, and patient enrollment has begun in the Virtue SAB US pivotal IDE coronary trial [2] Product Information - Orchestra BioMed's flagship products include Atrioventricular Interval Modulation (AVIM) Therapy and Virtue® Sirolimus AngioInfusion™ Balloon (Virtue SAB), both undergoing pivotal clinical trials [3] - AVIM Therapy targets uncontrolled hypertension and has FDA Breakthrough Device Designation, with an estimated 7.7 million patients in the U.S. affected [3] - Virtue SAB is a drug delivery angioplasty balloon system designed for treating atherosclerotic artery disease and has also received FDA Breakthrough Device Designation [3]

Core Insights - Alexandria Real Estate Equities, Inc. has announced the opening of Lilly Gateway Labs in San Diego, enhancing its collaborative Megacampus ecosystem aimed at biotechnology innovation [1][2][3] Company Overview - Alexandria Real Estate Equities, Inc. is a leading life science real estate investment trust (REIT) with a market capitalization of $25.7 billion and an asset base that includes 39.7 million RSF of operating properties and 4.4 million RSF of Class A/A+ properties under construction [5][6] Strategic Collaboration - The Lilly Gateway Labs operates in collaboration with Eli Lilly and Company, integrating Alexandria's real estate infrastructure with Lilly's scientific expertise and venture network [2][3] - This partnership aims to accelerate the development of early-stage biotech companies and foster collaboration between innovative biotechs and large pharmaceutical firms [3] Facility Features - The new Lilly Gateway Labs is located in a LEED Gold certified all-electric laboratory facility, featuring modular lab spaces, advanced scientific tools, and operational support services [4] - The facility is designed to support a diverse range of biotech companies focusing on various disease areas, including Alzheimer's, Parkinson's, cardiovascular diseases, and oncology [4] Ecosystem Development - Alexandria has been instrumental in developing the San Diego life science ecosystem since 1994, positioning the One Alexandria Square Megacampus as a hub for innovation and collaboration [3] - The Megacampus includes amenities such as a café, restaurant, event lawn, and proximity to renowned research institutions, enhancing the ability of tenants to attract and retain talent [3]

Core Insights - The city aims to enhance the biopharmaceutical industry by focusing on long-term development and innovation, emphasizing the importance of source innovation, result transformation, and project cultivation [1][2] - The city government is committed to creating a favorable industrial ecosystem to support the growth of the biopharmaceutical sector, with a focus on attracting leading enterprises and fostering local projects [2] Group 1: Industry Development Strategy - The city plans to build a biopharmaceutical innovation hub and industry cluster, enhancing confidence and focusing on key issues to strengthen the sector [1] - A spatial development framework is proposed, characterized by "one core leading, four parks collaborating, and the entire region forming a chain," aimed at increasing industry concentration and fostering flagship products and leading enterprises [2] Group 2: Innovation and Talent Support - Emphasis is placed on strengthening source innovation capabilities, optimizing enterprise innovation platforms, and accelerating the transformation of innovative results [2] - The city aims to support high-level talent development to bolster both foundational and applied research in the biopharmaceutical field [2] Group 3: Investment and Business Environment - The government is focused on attracting major biopharmaceutical enterprises and nurturing endogenous growth projects to ensure successful implementation and outcomes [2] - Continuous optimization of the business environment is planned, with regular engagement with enterprises to address their needs and develop targeted policies [2]